AI Article Synopsis

  • The UN has identified emergency contraceptive pills as a crucial and underused resource that could potentially save millions of women and children, especially highlighted in the context of recent U.S. Supreme Court decisions restricting abortion access.
  • Access to emergency contraception (EC) is hindered by various factors, including cost, misconceptions about its use, and political influences, leading to an expected increase in demand as abortion restrictions tighten.
  • Research shows that the levonorgestrel intrauterine device is effective as an emergency contraceptive, offering a promising alternative for those who may have other barriers to accessing traditional EC methods.

Article Abstract

Background: The UN Commission on Life-Saving Commodities for Women and Children identified emergency contraceptive pills as 1 of the 13 essential underused, low-cost, and high-impact commodities that could save the lives of millions of women and children worldwide. In the US, 2 emergency contraceptive regimens are currently approved, and their most plausible mechanism of action involves delaying and/or inhibiting ovulation.

Areas Of Uncertainty: Abortion and contraception are recognized as essential components of reproductive health care. In the US, in the wake of the Dobbs v. Jackson Women's Health Organization Supreme Court decision on June 24, 2022, 26 states began to or are expected to severely restrict abortion. It is anticipated that these restrictions will increase the demand for emergency contraception (EC). Several obstacles to EC access have been described, and these include cost, hurdles to over-the-counter purchase, low awareness, myths about their mechanisms of action, widespread misinformation, and barriers that special populations face in accessing them. The politicization of EC is a major factor limiting access. Improving sex education and health literacy, along with eHealth literacy, are important initiatives to improve EC uptake and access.

Data Sources: PubMed, The Guttmacher Institute, Society of Family Planning, American College of Obstetricians and Gynecologists, the World Health Organization, The United Nations.

Therapeutic Advances: A randomized noninferiority trial showed that the 52 mg levonorgestrel intrauterine device was noninferior to the copper intrauterine device when used as an EC method in the first 5 days after unprotected intercourse. This is a promising and highly effective emergency contraceptive option, particularly for overweight and obese patients, and a contraceptive option with a different bleeding profile than the copper intrauterine device.

Conclusions: EC represents an important facet of medicine and public health. The 2 medical regimens currently approved in the US are very effective, have virtually no medical contraindications, and novel formulations are actively being investigated to make them more convenient and effective for all patient populations. Barriers to accessing EC, including the widespread presence of contraception deserts , threaten to broaden and accentuate the already existing inequities and disparities in society, at a time when they have reached the dimensions of a public health crisis.

Download full-text PDF

Source
http://dx.doi.org/10.1097/MJT.0000000000001560DOI Listing

Publication Analysis

Top Keywords

emergency contraceptive
12
emergency contraception
8
women children
8
regimens currently
8
currently approved
8
health organization
8
intrauterine device
8
copper intrauterine
8
contraceptive option
8
public health
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!